DB
VYGR icon

Dmitry Balyasny’s Voyager Therapeutics VYGR Stock Holding History

Dmitry Balyasny’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-129,600
Closed -$3.59M – 1627
2019
Q2 		$3.59M Buy
+129,600
New +$2.97M 0.02% 707

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dmitry Balyasny's VYGR Position: Q2 2024 in Review

Dmitry Balyasny sold out of Voyager Therapeutics (VYGR) in Q2 2024, closing a stake of 21,341 shares — an estimated $199K sold.

Dmitry Balyasny first reported a position in VYGR in Q4 2017 and held it in 6 quarters. The position peaked at $2.72M in Q4 2017. 127 funds tracked by Wall St. Rank hold VYGR as of Q2 2024.

  • Dmitry Balyasny reported no remaining Voyager Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Dmitry Balyasny sold 21,341 Voyager Therapeutics shares in Q2 2024, an estimated $199K.
  • Dmitry Balyasny first reported a position in Voyager Therapeutics in Q4 2017 and held it in 6 quarters.
  • Dmitry Balyasny's Voyager Therapeutics position peaked at $2.72M in Q4 2017.
  • 127 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.